Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Onyx Pharmaceuticals Inc has given potential buyers, including Amgen Inc, access to trial data on its new cancer drug, removing a key hurdle that was holding up deal talks, according to three people familiar with the matter. The company’s attempt to sell itself for around $9.5 billion hit an impasse in recent weeks after lead bidder Amgen sought trial data about blood cancer drug Kyprolis - something that Onyx was reluctant to share, Reuters reported last week. Onyx made more information available this week to Amgen and other parties involved in the sale process, and is now waiting for a firm offer, the people said on Wednesday.
Help employers find you! Check out all the jobs and post your resume.
